Therapeutic Implications of the Tumor Microenvironment in Ovarian Cancer Patients Receiving PD-1/PD-L1 Therapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Nov 7

PMID 36341388

Authors

Yusha Wang

Lei Zhang

Yun Bai

Li Wang

Xuelei Ma

Affiliations

Soon will be listed here.

Abstract

Epithelial ovarian cancer (EOC) ranks as the second most common cause of gynecologic cancer death. The conventional treatment for patients with EOC is postoperative therapy along with platinum chemotherapy. However, a more efficient treatment regimen is of great need for these patients diagnosed with advanced disease (FIGO stages III-IV), whose survival is approximately 29%. Immunotherapy seems to be an encouraging therapeutic strategy for EOC. Given the crucial role in the complicated interactions between tumor cells and other cells, the tumor microenvironment (TME) influences the response to immunotherapy. In this review, we discuss feasible strategies for EOC immunotherapy by exploiting the reciprocity of cancer cells and the constituents of the TME.

Citing Articles

Tumor-infiltrating B cell-related lncRNA crosstalk reveals clinical outcomes and tumor immune microenvironment in ovarian cancer based on single-cell and bulk RNA-sequencing.

Huang Y, Gui Z, Wu M, Zhang M, Jiang Y, Ding Q Heliyon. 2024; 10(21):e39496.

PMID: 39559246 PMC: 11570495. DOI: 10.1016/j.heliyon.2024.e39496.

The roles of long non-coding RNAs in ovarian cancer: from functions to therapeutic implications.

Hu Z, Yuan L, Yang X, Yi C, Lu J Front Oncol. 2024; 14:1332528.

PMID: 38725621 PMC: 11079149. DOI: 10.3389/fonc.2024.1332528.

EFEMP2 upregulates PD-L1 expression via EGFR/ERK1/2/c-Jun signaling to promote the invasion of ovarian cancer cells.

Shen X, Jin X, Fang S, Chen J Cell Mol Biol Lett. 2023; 28(1):53.

PMID: 37420173 PMC: 10327401. DOI: 10.1186/s11658-023-00471-8.

References

Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan D, Poggi A . The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors. Int J Mol Sci. 2020; 21(9). PMC: 7247443. DOI: 10.3390/ijms21093125. View

Hagemann T, Wilson J, Kulbe H, Li N, Leinster D, Charles K . Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005; 175(2):1197-205. DOI: 10.4049/jimmunol.175.2.1197. View

Zhang S, Song X, Li Y, Ye L, Zhou Q, Yang W . Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy. Pharmacol Res. 2020; 161:105111. DOI: 10.1016/j.phrs.2020.105111. View

Munn D, Mellor A . IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016; 37(3):193-207. PMC: 4916957. DOI: 10.1016/j.it.2016.01.002. View

Dudek A, Martin S, Garg A, Agostinis P . Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. Front Immunol. 2013; 4:438. PMC: 3858649. DOI: 10.3389/fimmu.2013.00438. View

Poschke I, Mougiakakos D, Hansson J, Masucci G, Kiessling R . Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010; 70(11):4335-45. DOI: 10.1158/0008-5472.CAN-09-3767. View

Binnewies M, Pollack J, Rudolph J, Dash S, Abushawish M, Lee T . Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 2021; 37(3):109844. DOI: 10.1016/j.celrep.2021.109844. View

Vignali D, Collison L, Workman C . How regulatory T cells work. Nat Rev Immunol. 2008; 8(7):523-32. PMC: 2665249. DOI: 10.1038/nri2343. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

10.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

11.

Uppendahl L, Dahl C, Miller J, Felices M, Geller M . Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review. Front Immunol. 2018; 8:1825. PMC: 5760535. DOI: 10.3389/fimmu.2017.01825. View

12.

Drerup J, Deng Y, Pandeswara S, Padron A, Reyes R, Zhang X . CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. Cancer Res. 2020; 80(22):5063-5075. PMC: 7669742. DOI: 10.1158/0008-5472.CAN-20-0002. View

13.

Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W . Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006; 203(12):2691-702. PMC: 2118163. DOI: 10.1084/jem.20061104. View

14.

Parker K, Beury D, Ostrand-Rosenberg S . Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res. 2015; 128:95-139. PMC: 4662416. DOI: 10.1016/bs.acr.2015.04.002. View

15.

Motta J, Rumjanek V . Sensitivity of Dendritic Cells to Microenvironment Signals. J Immunol Res. 2016; 2016:4753607. PMC: 4819111. DOI: 10.1155/2016/4753607. View

16.

Cao X, Cai S, Fehniger T, Song J, Collins L, Piwnica-Worms D . Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007; 27(4):635-46. DOI: 10.1016/j.immuni.2007.08.014. View

17.

Xiong Y, McDonald L, Russell D, Kelly R, Wilson K, Mehrotra M . Hematopoietic stem cell-derived adipocytes and fibroblasts in the tumor microenvironment. World J Stem Cells. 2015; 7(2):253-65. PMC: 4369485. DOI: 10.4252/wjsc.v7.i2.253. View

18.

Bronte V, Zanovello P . Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005; 5(8):641-54. DOI: 10.1038/nri1668. View

19.

Fiani M, Barreca V, Sargiacomo M, Ferrantelli F, Manfredi F, Federico M . Exploiting Manipulated Small Extracellular Vesicles to Subvert Immunosuppression at the Tumor Microenvironment through Mannose Receptor/CD206 Targeting. Int J Mol Sci. 2020; 21(17). PMC: 7503580. DOI: 10.3390/ijms21176318. View

20.

Kato S, Abarzua-Catalan L, Trigo C, Delpiano A, Sanhueza C, Garcia K . Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: an explanation for poor outcomes in obese women. Oncotarget. 2015; 6(25):21100-19. PMC: 4673253. DOI: 10.18632/oncotarget.4228. View